Abstract:Snake bite is a neglected disease that affects millions of people worldwide. WHO reported approximately 5 million people are bitten by various species of snakes each year, resulting in nearly 1 million deaths and an additional three times cases of permanent disability. Snakes utilize the venom mainly for immobilization and digestion of their prey. Snake venom is a composition of proteins and enzymes which is responsible for its diverse pharmacological action. Snake venom phospholipase A2 (SvPLA2) is an enzyme that is present in every snake species in different quantities and is known to produce remarkable functional diversity and pharmacological action like inflammation, necrosis, myonecrosis, hemorrhage, etc. Arachidonic acid, a precursor to eicosanoids, such as prostaglandins and leukotrienes, is released when SvPLA2 catalyzes the hydrolysis of the sn-2 positions of membrane glycerophospholipids, which is responsible for its actions. Polyvalent antivenom produced from horses or lambs is the standard treatment for snake envenomation, although it has many drawbacks. Traditional medical practitioners treat snake bites using plants and other remedies as a sustainable alternative. More than 500 plant species from more than 100 families reported having venom-neutralizing abilities. Plant-derived secondary metabolites have the ability to reduce the venom's adverse consequences. Numerous studies have documented the ability of plant chemicals to inhibit the enzymes found in snake venom. Research in recent years has shown that various small molecules, such as varespladib and methyl varespladib, effectively inhibit the PLA2 toxin. In the present article, we have overviewed the knowledge of snake venom phospholipase A2, its classification, and the mechanism involved in the pathophysiology of cytotoxicity, myonecrosis, anticoagulation, and inflammation clinical application and inhibitors of SvPLA2, along with the list of studies carried out to evaluate the potency of small molecules like varespladib and secondary metabolites from the traditional medicine for their anti-PLA2 effect.

From Snake Venom's Disintegrins and C-Type Lectins to Anti-Platelet Drugs

Snake venom disintegrins update: insights about new findings

LX0702, a Novel Snake Venom Peptide Derivative, Inhibits Thrombus Formation Via Affecting the Binding of Fibrinogen with GPIIb/IIIa

Bioactive Peptides and Proteins As Alternative Antiplatelet Drugs

Snake Venoms in Drug Discovery: Valuable Therapeutic Tools for Life Saving

A Novel Direct Factor Xa Inhibitory Peptide with Anti-Platelet Aggregation Activity from Agkistrodon Acutus Venom Hydrolysates

Optimizing drug discovery for snakebite envenoming via a high-throughput phospholipase A2 screening platform

Snake Venom Proteins and Platelet Thrombus Formation

Varespladib Inhibits the Phospholipase A2 and Coagulopathic Activities of Venom Components from Hemotoxic Snakes

Purification and Characterization of a Novel Antiplatelet Peptide from Deinagkistrodon acutus Venom

Snakebite drug discovery: high-throughput screening to identify novel snake venom metalloproteinase toxin inhibitors

Isolation and Characterization of a Novel Antithrombotic Peptide from Enzymatic Hydrolysate of Agkistrodon acutus Venom

Computer-aided drug design of novel PLA2 inhibitor candidates for treatment of snakebite

Discovery of Natural-pan Inhibitors by Targeting Snake Venom Secretory Phospholipase A2 through Computational Approaches

Unraveling snake venom phospholipase A2: an overview of its structure, pharmacology, and inhibitors

Hemorrhagic fibrino(geno)lytic enzymes from snake venom

A Pharmacoinformatic Study of Atrolysin Inhibitors

Reversible Thrombocytopenia of Functional Platelets after Nose-horned Viper Envenomation is Induced by a Snaclec

Platelet Desialylation Is a Novel Mechanism and Therapeutic Target in Daboia siamensis and Agkistrodon halys Envenomation-Induced Thrombocytopenia

Viper venoms drive the macrophages and hepatocytes to sequester and clear platelets: novel mechanism and therapeutic strategy for venom-induced thrombocytopenia

Snake venom toxins: Potential anticancer therapeutics